知镜 Cognispect · 医学文献与研究工作台

The PREVENT equations evidence appraisal of validation and clinical implications.

Mortada I, Elkolaly EA, Lee AW, Woods R, Qadeer A, Albayyaa M, Blackwell TA, Jneid H.
Current problems in cardiology · 2026-09-29 · PMID 42810478

文献摘要

The American Heart Association's PREVENT equations offer a contemporary, race-free alternative to the Pooled Cohort Equations (PCE), incorporating kidney function to estimate 10- and 30-year risks of atherosclerotic cardiovascular disease (ASCVD), heart failure, and total CVD. PREVENT-ASCVD is now recommended for primary-prevention risk assessment in the 2026 multisociety dyslipidemia guidelines, replacing the PCE, making its real-world performance immediately consequential. PREVENT generally preserves discrimination, but calibration varies across populations, with possible overestimation or underestimation. It often lowers estimated risk and modeled eligibility for statin or antihypertensive therapy versus the PCE. Performance is favorable in several general and older-adult cohorts, but underestimation is concerning in people with HIV, rheumatoid arthritis, selected international cohorts, and statin-naïve adults. Coronary artery calcium can refine selected estimates, though no trial has shown PREVENT-guided care improves outcomes. This narrative review appraises external validation, calibration, and reclassification behavior, evaluates effects on treatment eligibility, and identifies evidence gaps, concluding that implementation should remain population-sensitive with local validation and recalibration when appropriate.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。